Jeuveau maker posts 21% YoY growth and narrows losses as profitability streak extends.
Evolus reported Q2 2026 revenue of $84.1 million, up 21% year-over-year, and raised full-year 2026 guidance following the beat. The neuromodulator and device company achieved break-even on an adjusted EBITDA basis, extending its streak of profitability quarters as gross margins held steady.
Jeuveau continues to drive growth across the toxin portfolio, with the company maintaining pricing discipline and market share gains in the U.S. aesthetic market. Perceptive Advisors LLC acquired a new stake in Evolus during the quarter, signaling institutional confidence in the turnaround narrative.
Revenue up 21% YoY; adjusted EBITDA margin now positive.
For practice owners tracking the competitive toxin landscape, Evolus's sustained margin expansion and guidance raise matter: the company is proving unit economics can improve even as the market fragments. Jeuveau's trajectory—especially relative to Revance's Daxxify and AbbVie's BOTOX—remains a bellwether for non-legacy toxin adoption.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
